Poisoned in the Womb: When Medicine's Mistakes Echo Through Generations - Jill Escher (#19)
Jill Escher's investigation into her own family's neurodevelopmental history opens a disturbing window onto a medical scandal that crossed the Atlantic decades ago. Synthetic steroid hormones were prescribed to pregnant women across Europe — in the Netherlands, France and beyond — with consequences still unfolding today. As European gender clinics grapple with soaring referrals, many involving autistic young people, Escher's argument that prenatal hormonal disruption may link the autism and gender-dysphoria epidemics deserves urgent attention from European researchers, regulators and clinicians.
Jill Escher is not a scientist by training, but she became one by necessity. The president of the National Council on Severe Autism in the United States, Escher has two profoundly autistic sons and spent years searching for an explanation that went beyond genetics alone. What she found in a set of medical records from 1965 — documentation that her mother had received weekly injections of synthetic steroid hormones throughout her pregnancy — sent her down a research path that connects mid-twentieth-century medical mistakes to the neurodevelopmental crises of the present day. The drug at the centre of Escher's account will not be unfamiliar to European listeners. DES, diethylstilbestrol, was a synthetic oestrogen prescribed to millions of pregnant women across the United States and large parts of Europe, sold under various brand names and believed at the time to prevent miscarriage. Its catastrophic effects on the reproductive systems of daughters born to DES mothers became one of the defining pharmaceutical scandals of the twentieth century. What Escher argues — and what the medical establishment has been slow to accept — is that the harm extended further still. Epigenetic alterations triggered by prenatal hormonal disruption may have changed gene expression across not one but two subsequent generations. In this episode, Escher develops the mechanism she finds most compelling: that certain brains, exposed in utero to powerful synthetic hormones, are wired differently from the outset in ways that can manifest as autism spectrum conditions or other forms of neurodivergence. She then turns to a question that has become central to the gender medicine debate — why so many young people presenting at gender clinics are also autistic or otherwise neurodivergent. The correlation is well documented; the causal explanation is not. Escher's hypothesis offers one answer that mainstream clinical bodies have not been willing to examine with any seriousness. For European clinicians and policymakers, this has concrete implications. Sweden and Finland have already restricted hormonal and surgical interventions for minors after systematic evidence reviews concluded that the risk profile was poorly understood and the benefits unproven. Across the continent, gender clinic referrals have risen sharply over the past decade, and neurodivergent young people are consistently overrepresented among those referred. If prenatal hormonal exposures — including anti-miscarriage drugs that remained in clinical use in some countries until 2023 — have contributed to both the neurodevelopmental and gender-dysphoria epidemics, the scale of unacknowledged harm is considerable. What Escher calls for is not a retreat from medicine but a return to honest science: independent research, transparent acknowledgement of past errors and the institutional courage that has been conspicuously absent from regulators and professional bodies on both sides of the Atlantic. For the European psychiatrists, researchers and policymakers who are already reappraising the evidence base for paediatric gender medicine, this episode offers a framework — unsettling, meticulously personal, and scientifically grounded — for asking why so many children are arriving at gender clinics in the first place, and what medicine may have set in motion long before they were born.
